« Return to News | Clinical Intelligence

Europe approves Byetta with basal insulin for T2D

Monday, March 26, 2012 02:47 PM

The European Commission has granted Amylin Pharmaceuticals and Eli Lilly marketing authorization for Byetta (exenatide twice-daily) as an adjunctive therapy to basal insulin for the treatment of type 2 diabetes (T2D).

The authorization provides a new option for the many patients with T2D who are not achieving adequate glycemic control with metformin or Actos (pioglitazone).

The main study included in the European marketing authorization submission package was a double-blind, 30-week clinical trial in which 10 micrograms of Byetta or placebo were added to existing insulin glargine therapy (with or without metformin, pioglitazone or both), which was titrated to achieve target fasting glucose levels. Results from the study demonstrated that Byetta significantly reduced A1C numbers compared to placebo. Patients who added Byetta to their insulin glargine regimen also saw their weight decrease by an average of 4 pounds.

Byetta will be marketed outside the U.S. by both Lilly and Amylin until the latter assumes complete responsibility once the pair’s decade-long collaboration dissolves. Amylin anticipates working with one or more partners outside the U.S. in order to maximize the global potential of the molecule and achieve greater operational flexibility and efficiency.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.